Key Financial Inc Lowers Stake in Johnson & Johnson (NYSE:JNJ)

Key Financial Inc decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.3% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 27,519 shares of the company’s stock after selling 90 shares during the period. Johnson & Johnson accounts for approximately 1.0% of Key Financial Inc’s portfolio, making the stock its 23rd largest holding. Key Financial Inc’s holdings in Johnson & Johnson were worth $4,022,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Innealta Capital LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth $27,000. Christopher J. Hasenberg Inc purchased a new position in Johnson & Johnson during the first quarter worth about $31,000. Vermillion & White Wealth Management Group LLC acquired a new stake in Johnson & Johnson in the 4th quarter worth about $44,000. MFA Wealth Advisors LLC purchased a new stake in Johnson & Johnson in the 2nd quarter valued at about $43,000. Finally, Grayhawk Investment Strategies Inc. increased its stake in shares of Johnson & Johnson by 528.6% during the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after acquiring an additional 259 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on JNJ shares. TD Securities lowered their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. TD Cowen dropped their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, July 18th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Monday, August 5th. Sanford C. Bernstein upped their price target on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Finally, Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their price objective for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Stock Up 1.0 %

Shares of NYSE:JNJ traded up $1.63 during mid-day trading on Friday, hitting $165.86. 7,441,042 shares of the company traded hands, compared to its average volume of 7,271,470. The firm’s 50 day simple moving average is $155.34 and its 200 day simple moving average is $153.45. The firm has a market cap of $399.17 billion, a P/E ratio of 10.34, a PEG ratio of 2.63 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $165.98.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The company had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business’s quarterly revenue was up 4.3% on a year-over-year basis. During the same quarter last year, the firm posted $2.80 earnings per share. On average, equities analysts anticipate that Johnson & Johnson will post 10.07 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 2.99%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s payout ratio is currently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.